A clinical trial update dated August 26, 2026 reports on a study titled "An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events." The trial, registered as NCT07503028, is listed in Early Phase 1 and is currently enrolling by invitation.
According to the registration, the study is evaluating CRG-002, an allogeneic iPSC-derived pancreatic islet cell product, in diabetic patients who experience hypoglycemia unawareness or severe hypoglycemic events. The listing does not report results, efficacy data, or safety outcomes at this stage. Enrollment status is limited to invitation only, meaning participation is restricted to selected candidates rather than open recruitment.
No additional trial details, such as expected completion dates or specific endpoints, were included in this update. The information provided reflects only the trial's current registration status as of the listed date. Readers seeking further specifics should consult the official registry listing directly for the most complete and current record.
For background on exenatide itself, readers can consult the compound overview for additional context.